Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
265 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Theravance Biopharma, Inc.’s names, not what it holds today.
Patents granted
265
265 utility, 1976 to Dec 31, 2025
Granted in 2025
7
Against 7 in 2024 and 27 in 2023
Applications published
242
4 of them in 2025
Names they are printed under
3
a subsidiary
By yearGrantedApplications published
'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals63
Organic fine chemistry11
Chemical engineering1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
Theravance Biopharma R&D IP, LLC a subsidiary
US, as the owner printed on each patent
209 publishedTHERAVANCE BIOPHARMA R&D IP, LLC a subsidiary
named as the applicant on its applications, in US
31 publishedTHERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC a subsidiary
US, as the owner printed on each patent
2 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Aug 26, 2025 | 12,398,135 | Dimethyl amino azetidine amides as JAK inhibitors | Organic fine chemistry | Theravance Biopharma R&D IP, LLC |
| Aug 12, 2025 | 12,384,761 | Imidazolo indazole compounds as JAK inhibitors | Organic fine chemistry | Theravance Biopharma R&D IP, LLC |
| Jul 15, 2025 | 12,358,931 | 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitor | Pharmaceuticals | Theravance Biopharma R&D IP, LLC |
| Jul 8, 2025 | 12,351,561 | Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof | Pharmaceuticals | Theravance Biopharma R&D IP, LLC |
| Apr 29, 2025 | 12,285,417 | Methods for treating chronic obstructive pulmonary disease | Pharmaceuticals | Theravance Biopharma R&D IP, LLC |
| Mar 25, 2025 | 12,258,316 | Biphenyl compounds useful as muscarinic receptor antagonists | Pharmaceuticals | Theravance Biopharma R&D IP, LLC |
| Mar 4, 2025 | 12,239,638 | Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound | Pharmaceuticals | Theravance Biopharma R&D IP, LLC |
| Dec 24, 2024 | 12,172,994 | Pyrimidine compound as JAK kinase inhibitor | Pharmaceuticals | Theravance Biopharma R&D IP, LLC |
| Oct 22, 2024 | 12,122,773 | Crystalline hydrate of a JAK inhibitor compound | Pharmaceuticals | Theravance Biopharma R&D IP, LLC |
| Jul 30, 2024 | 12,048,692 | Methods for treating chronic obstructive pulmonary disease | Pharmaceuticals | Theravance Biopharma R&D IP, LLC |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Sep 18, 2025 | 2025/0288561 | NEZULCITINIB FOR DELIVERY BY NEBULIZED ORAL INHALATION | Pharmaceuticals | THERAVANCE BIOPHARMA R&D IP, LLC |
| Jun 5, 2025 | 2025/0179019 | CRYSTALLINE FREEBASE FORMS OF A BIPHENYL COMPOUND | Pharmaceuticals | THERAVANCE BIOPHARMA R&D IP, LLC |
| May 1, 2025 | 2025/0136550 | PROCESSES FOR PREPARING REVEFENACIN AND COMPOSITIONS COMPRISING THE SAME | Organic fine chemistry | THERAVANCE BIOPHARMA R&D IP, LLC |
| Jan 30, 2025 | 2025/0034131 | DIMETHYL AMINO AZETIDINE AMIDES AS JAK INHIBITORS | Organic fine chemistry | THERAVANCE BIOPHARMA R&D IP, LLC · patent 12,398,135 granted from it |
| Oct 3, 2024 | 2024/0327360 | CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF | Pharmaceuticals | THERAVANCE BIOPHARMA R&D IP, LLC · patent 12,351,561 granted from it |
| Sep 26, 2024 | 2024/0316024 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | Pharmaceuticals | THERAVANCE BIOPHARMA R&D IP, LLC |
| May 16, 2024 | 2024/0158389 | PYRIMIDINE COMPOUND AS JAK KINASE INHIBITOR | Pharmaceuticals | THERAVANCE BIOPHARMA R&D IP, LLC · patent 12,172,994 granted from it |
| Apr 25, 2024 | 2024/0132520 | NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS | Pharmaceuticals | THERAVANCE BIOPHARMA R&D IP, LLC · patent 12,358,931 granted from it |
| Mar 21, 2024 | 2024/0092758 | IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS | Organic fine chemistry | THERAVANCE BIOPHARMA R&D IP, LLC · patent 12,384,761 granted from it |
| Jan 25, 2024 | 2024/0025897 | CRYSTALLINE HYDRATE OF A JAK INHIBITOR COMPOUND | Pharmaceuticals | THERAVANCE BIOPHARMA R&D IP, LLC · patent 12,122,773 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 7 · Organic fine chemistry 3.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.